Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Background: Clozapine is of high clinical relevance for the management of both treatment-resistant schizophrenia and psychotic disturbances with concurrent drug misuse. Although the molecule presents with a range of well-known side-effects, its discontinuation/withdrawal syndrome has been only anecdotally described. Aims: the 2005–2018 European Medicines Agency (EMA) dataset of Adverse Drug Reactions (ADRs) was analyzed to identify and describe possible clozapine withdrawal- and misuse-/abuse-/dependence-related issues. Method: A descriptive analysis of clozapine-related ADRs was performed when available, data on ADRs’ outcome, dosage, and possible concomitant drug(s) were considered. Results: Out of 11,847 clozapine-related ADRs, some 599 (5.05%) were related to misuse/abuse/dependence/withdrawal issues, including 258 withdrawal-related (43.1%); 241 abuse-related (40.2%); and 80 intentional product misuse-related (13.3%) ADRs. A small number of overdose- and suicide-related ADRs were reported as well. Clozapine was typically (69.2%) identified alone, and most (84.7%) fatalities/high-dosage intake instances were reported in association with a history of substance abuse. Conclusions: Previous suggestions about the possibility of a clozapine discontinuation/withdrawal occurrence are here supported, but further studies are needed. However, the misuse/abuse cases here identified might be difficult to interpret, given the lack of studies highlighting the possible recreational use of clozapine. The high-dosage intake, fatal outcomes and clozapine/polydrug abuse issues reported here may, however, be a reason for concern.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In line with these observations, both the last decade European Medicines Agency (EMA) and the UK-based Yellow Card Scheme pharmacovigilance adverse drug reactions (ADRs) data (40) showed that, in comparison with venlafaxine, bupropion may possess a higher stimulant-like recreational activity.”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [40]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Conversely, the occurrence of a withdrawal syndrome was confirmed to be a significant issue for venlafaxine-treated patients (40).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 1×
“The clozapine agonist action on GABA receptors can explain both the drug-drug interaction between clozapine and benzodiazepines, and the flumazenil therapeutic effect in clozapine intoxication cases [6]; and (e) a modification of norepinephrine levels, with clozapine abrupt discontinuation in chronic patients possibly…”
BackgroundFava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436 · cited 1×
“As it may occur with remaining psychotropics, such as antidepressants [69,70], the existence of a discontinuation syndrome following an abrupt stoppage of, or marked reduction in, the dosage of a drug taken on a regular basis does not necessarily mean that a drug causes dependence.”
BackgroundThe delta opioid receptor: an evolving target for the treatment of brain disorders
Pradhan, A. A., Befort, K., Nozaki, C., Gavériaux-Ruff, C., & Kieffer, B. L. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.06.008 · Cited by 365 · cited 1×
“Hypothetically, putative levels of clozapine misuse liability might be tentatively explained considering the range of its pharmacodynamics activities, and the occurrence of rewarding and pleasurable effects due to the agonism at both delta-opioid [13,17,75] and cannabinoid CB1 receptors [18]; and the antagonism at mus…”
BackgroundNovel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321 · cited 1×
“In particular, the positive symptoms of schizophrenia are generally exacerbated by the intake of stimulant drugs, such as cocaine, amphetamine derivatives [24], and synthetic cathinones [25].”
BackgroundSelf-citationAntidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
An overview of the mechanism of action of clozapine.
Meltzer, H. Y. (1994) · PubMed · Cited by 282
The link between schizophrenia and substance use disorder: A unifying hypothesis
Khokhar, J. Y., Dwiel, L. L., Henricks, A. M., Doucette, W. T., & Green, A. I. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.016 · Cited by 281 · cited 1×
“Substance use disorders (SUDs), typically involving alcohol, cannabis, and cocaine, commonly occur in patients with schizophrenia, supposedly due to epidemiological and genetic determinants of risk for both psychosis and addiction [1,16].”
BackgroundClinical pharmacology of atypical antipsychotics: an update
Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., & Altamura, A. C. (2014) · Technische Universität Dortmund · doi:10.17877/de290r-7037 · Cited by 250 · cited 3×
“Clozapine is metabolized by CYP450 enzymes, specifically by CYP450 1A2, 2D6 and 3A4 enzymes [5], and its metabolism may be influenced by CYP450 1A2 inhibitors, such as fluvoxamine and ciprofloxacin [14].”
BackgroundClozapine: a review of clinical practice guidelines and prescribing trends
Warnez, S., & Alessi-Severini, S. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-102 · Cited by 234
Moncrieff, J. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00787.x · Cited by 231
Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz007 · Cited by 194 · cited 1×
“, pharmacist, physician); outcomes (fatal, recovered, resolved); clozapine dosage; possible concomitant drug(s); and diagnosis/reporter’s comments, if recorded [37].”
Self-citationUnique Effects of Clozapine: A Pharmacological Perspective
Khokhar, J. Y., Henricks, A. M., Sullivan, E. D. K., & Green, A. I. (2018) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.09.009 · Cited by 182 · cited 4×
“Clozapine was first synthesized in 1959 [1] and made available on the European market in 1971 for the treatment of schizophrenia [2].”
BackgroundInfluentialPromoting and Protecting Public Health: How the European Union Pharmacovigilance System Works
Santoro, A., Genov, G., Spooner, Á., Raine, J. M., & Arlett, P. R. (2017) · Drug Safety · doi:10.1007/s40264-017-0572-8 · Cited by 164 · cited 1×
“One could argue that this upward trend may have been associated with a range of factors, including the increasing rates of worldwide availability of clozapine due to an overwhelming evidence of its effectiveness [2,49–51] and/or a major awareness of the relevant and significant impact of pharmacovigilance processes an…”
BackgroundZimmet, S. V., Strous, R. D., Burgess, E. S., Kohnstamm, S., & Green, A. I. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200002000-00016 · Cited by 163 · cited 1×
“Due to clozapine’s effectiveness, there has been support for considering the molecule in limiting substance use in patients with schizophrenia [26], to achieve both a reduction in substance use [27,28] and an improvement in positive/negative schizophrenia symptoms [29].”
BackgroundDelta opioid receptors in brain function and diseases
Chu Sin Chung, P., & Kieffer, B. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.06.003 · Cited by 159
(1997) · PubMed · Cited by 149
Brunette, M. F., Drake, R. E., Xie, H., McHugo, G. J., & Green, A. I. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl003 · Cited by 142 · cited 1×
“Due to clozapine’s effectiveness, there has been support for considering the molecule in limiting substance use in patients with schizophrenia [26], to achieve both a reduction in substance use [27,28] and an improvement in positive/negative schizophrenia symptoms [29].”
BackgroundClozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia
Barber, S., Olotu, U., Corsi, M., & Cipriani, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006324.pub3 · Cited by 141
Managing Suicide Risk in Patients with Schizophrenia
Kasckow, J., Felmet, K., & Zisook, S. (2011) · CNS Drugs · doi:10.2165/11586450-000000000-00000 · Cited by 133 · cited 1×
“These rates are a reason for concern but seem to be consistent with the suggestion that those subjects diagnosed with treatment-resistant schizophrenia, and hence, who are typically being prescribed with clozapine, present with a higher risk of attempted/completed suicide in comparison to the general population [80].”
ResultReview of withdrawal catatonia: what does this reveal about clozapine?
Lander, M., Bastiampillai, T. J., & Sareen, J. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0192-9 · Cited by 122
Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal
Shiovitz, T. M., Welke, T. L., Tigel, P. D., Anand, R., Hartman, R. D., Sramek, J. J., Kurtz, N. M., & Cutler, N. R. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.4.591 · Cited by 104
Geographical and temporal variations in clozapine prescription for schizophrenia
Nielsen, J., Røge, R., Schjerning, O., Sørensen, H. J., & Taylor, D. M. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.03.003 · Cited by 102
Antidepressant discontinuation syndrome
Gabriel, M., & Sharma, V. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.160991 · Cited by 98 · cited 1×
“As it may occur with remaining psychotropics, such as antidepressants [69,70], the existence of a discontinuation syndrome following an abrupt stoppage of, or marked reduction in, the dosage of a drug taken on a regular basis does not necessarily mean that a drug causes dependence.”
Backgroundα2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs
Kalkman, H. O., & Loetscher, E. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01308-6 · Cited by 96 · cited 1×
“Conversely, the clinical effects of the reported interactions at 5HT2C; 5HT1A; 5-HT6; and 5-HT7 receptors [6] might be less clear; (3) α2C-adrenergic receptor blockade; this may contribute to the clozapine-related improvement of cognitive function [7]; (4) significant antimuscarinic and antihistaminergic H1 effects, w…”
BackgroundClozapine combined with different antipsychotic drugs for treatment resistant schizophrenia
Cipriani, A., Boso, M., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006324.pub2 · Cited by 95 · cited 1×
“In being a prescribed drug of highly significant clinical value [85], increased awareness is essential towards prevention, diagnosis, and treatment of cases of clozapine abuse/recreational use in patients diagnosed with schizophrenia [86].”
BackgroundSchifano, F., Chiappini, S., Corkery, J., & Guirguis, A. (2018) · Brain Sciences · doi:10.3390/brainsci8040073 · Cited by 93
Self-citationKrause, M., Huhn, M., Schneider-Thoma, J., Bighelli, I., Gutsmiedl, K., & Leucht, S. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.1105 · Cited by 86 · cited 1×
“Due to clozapine’s effectiveness, there has been support for considering the molecule in limiting substance use in patients with schizophrenia [26], to achieve both a reduction in substance use [27,28] and an improvement in positive/negative schizophrenia symptoms [29].”
BackgroundFatalities Associated with Therapeutic Use and Overdose of Atypical Antipsychotics
Trenton, A., Currier, G. W., & Zwemer, F. L. (2003) · CNS Drugs · doi:10.2165/00023210-200317050-00002 · Cited by 83
Therapeutic drug monitoring of clozapine and relapse a retrospective study of routine clinical data
Ulrich, S., Baumann, B., Wolf, R. C., Lehmann, D., Peters, B., Bogerts, B., & Meyer, F. P. (2003) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp41003 · Cited by 80 · cited 1×
“This may involve possible severe and long-lasting symptoms [10,59,67,84].”
BackgroundLopez-Gil, X., Artigas, F., & Adell, A. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361416 · Cited by 77 · cited 1×
“Finally, further pharmacological clozapine activities which should be better understood in terms of their clinical effects may include both interaction with GABA-B receptors [22]; and antagonistic actions at D (2)/D (3)/D (4) receptors [23].”
BackgroundThe clinical challenges of synthetic cathinones
Schifano, F., Napoletano, F., Arillotta, D., Zangani, C., Gilgar, L., Guirguis, A., Corkery, J. M., & Vento, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14132 · Cited by 73 · cited 1×
“In particular, the positive symptoms of schizophrenia are generally exacerbated by the intake of stimulant drugs, such as cocaine, amphetamine derivatives [24], and synthetic cathinones [25].”
BackgroundSelf-citationSignificant interaction between clozapine and cocaine in cocaine addicts
Farren, C. K., Hameedi, F. A., Rosen, M. A., Woods, S. W., Jatlow, P. I., & Kosten, T. R. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00114-3 · Cited by 71 · cited 1×
“Indeed, clozapine pre-treatment may increase cocaine concentrations, but significantly reduce subjective responses to cocaine [78].”
BackgroundClozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex
Schwieler, L., Engberg, G., & Erhardt, S. (2004) · Synapse · doi:10.1002/syn.20008 · Cited by 66 · cited 1×
“More precisely, clozapine interacts with the N-methylD-aspartate (NMDA) receptor complex, affecting either the glycine site of the NMDA receptor or tentatively inhibiting the glycine transporter [12].”
BackgroundThe nature of the discontinuation syndrome associated with antidepressant drugs.
Shelton, R. C. (2006) · PubMed · Cited by 60
Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00046 · Cited by 55
Self-citationOkhuijsen‐Pfeifer, C., Sterk, A. Y., Horn, I., Terstappen, J., Kahn, R. S., & Luykx, J. J. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.01.017 · Cited by 53 · cited 1×
“Due to clozapine’s effectiveness, there has been support for considering the molecule in limiting substance use in patients with schizophrenia [26], to achieve both a reduction in substance use [27,28] and an improvement in positive/negative schizophrenia symptoms [29].”
BackgroundNIMH Activities: Clinical Implications of Clozapine Discontinuation: Report of an NIMH Workshop
Shore, D. L., Matthews, S., Cott, J. M., & Lieberman, J. A. (1995) · Schizophrenia Bulletin · doi:10.1093/schbul/21.2.333 · Cited by 51
Bilbily, J., McCollum, B., & de León, J. (2017) · Case Reports in Psychiatry · doi:10.1155/2017/2402731 · Cited by 50
Clozapine decreases [3H] CP 55940 binding to the cannabinoid1 receptor in the rat nucleus accumbens
Sundram, S., Copolov, D., & Dean, B. (2005) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-005-1074-2 · Cited by 49 · cited 2×
“Moreover, both clozapine and its major metabolite N-desmethylclozapine behave as: (i) delta-opioid receptor agonists [13–17]; (ii) cannabinoid CB1 receptor agonists [18]; and (iii) antagonists at muscarinic receptors [8].”
BackgroundEvidence that clozapine directly interacts on the GABAB receptor
Wu, Y., Blichowski, M., Daskalakis, Z. J., Wu, Z., Liu, C. C., Cortez, M. A., & Snead, O. C. (2011) · NeuroReport · doi:10.1097/wnr.0b013e328349739b · Cited by 48 · cited 1×
“Finally, further pharmacological clozapine activities which should be better understood in terms of their clinical effects may include both interaction with GABA-B receptors [22]; and antagonistic actions at D (2)/D (3)/D (4) receptors [23].”
BackgroundYeh, W., Lee, J. W. Y., Cheng, T.-C., Wen, J.-K., & Chen, W.-H. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000145506.99636.1b · Cited by 48
Bersani, F. S., Corazza, O., Simonato, P., Mylokosta, A., Levari, E., Lovaste, R., & Schifano, F. (2013) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2013.04.013 · Cited by 47
Self-citationChiappini, S., & Schifano, F. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000814 · Cited by 44
Self-citationSchifano, F., & Chiappini, S. (2018) · PLOS ONE · doi:10.1371/journal.pone.0204443 · Cited by 44
Self-citationIntentional Recreational Abuse of Quetiapine Compared to Other Second-generation Antipsychotics
Klein, L., Bangh, S., & Cole, J. (2017) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2016.10.32322 · Cited by 42 · cited 1×
“[74] suggested that clozapine and olanzapine were significantly associated with frequent instances of severe central effects, including: lethargy/drowsiness/slurred speech; agitation/irritability; confusion and hallucinations.”
Clozapine-Withdrawal Catatonia
Wadekar, M., & Syed, S. (2010) · Psychosomatics · doi:10.1016/s0033-3182(10)70710-6 · Cited by 41
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40 · cited 1×
“In fact, acting as a 5-HT2A antagonist, long-term clozapine use may be associated with receptor downregulation, and thus, its abrupt discontinuation might lead to receptors’ upregulation [65,66]; d) a sudden decrease in gamma-aminobutyric acid (GABA) activity, with the development of catatonic symptoms which may inclu…”
BackgroundSerotonin Syndrome Associated With Clozapine Withdrawal
Stevenson, E., Schembri, F., Green, D. M., & Burns, J. D. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.95 · Cited by 39 · cited 3×
“This may involve possible severe and long-lasting symptoms [10,59,67,84].”
BackgroundAcute Clozapine Overdose: Plasma Concentration and Outcome
Broich, K., Heinrich, S., & Marneros, A. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979318 · Cited by 39 · cited 1×
“altered state of consciousness [4,81,82]; clozapine high-dosage ingestion may be associated with a mortality rate of approximately 12% [83], with fatalities most typically being associated with cardiac insufficiency and aspiration pneumonia observed with dosages higher than 2 g [45–48].”
BackgroundEvoy, K. E., Teng, C., Encarnacion, V., Frescas, B., Hakim, J., Saklad, S. R., & Frei, C. R. (2019) · Substance Abuse Research and Treatment · doi:10.1177/1178221819844205 · Cited by 39
Krämer, I., Rauber‐Lüthy, C., Kupferschmidt, H., Krähenbühl, S., & Ceschi, A. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181f0ec55 · Cited by 38 · cited 1×
“Clozapine overdose may be lethal due to changes in heart rhythm, respiratory depression, and altered state of consciousness [4,81,82]; clozapine high-dosage ingestion may be associated with a mortality rate of approximately 12% [83], with fatalities most typically being associated with cardiac insufficiency and aspira…”
BackgroundIs There a Potential of Misuse for Venlafaxine and Bupropion?
Schifano, F., & Chiappini, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00239 · Cited by 38 · cited 1×
“Consistent with this, symptoms appear to regress rapidly with the help of anti-cholinergic drugs; c) a serotonergic syndrome, which may occur even without the concomitant use of a serotonergic agent [10,39,61].”
BackgroundSelf-citationQuetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug Seeking Behavior?
Kim, S., Lee, G., Kim, E., Jung, H., & Chang, J. (2017) · Journal of Research in Pharmacy Practice · doi:10.4103/2279-042x.200987 · Cited by 36
Quetiapine Abuse Fourteen Years Later: Where Are We Now? A Systematic Review
Vento, A. E., Kotzalidis, G. D., Cacciotti, M., Papanti, G. D., Orsolini, L., Rapinesi, C., Savoja, V., Calabrò, G., CASALE, A. D., Piacentino, D., et al. (2019) · Substance Use & Misuse · doi:10.1080/10826084.2019.1668013 · Cited by 36
Self-citationClozapine cases with fatal, toxic or therapeutic concentrations
Worm, K., Kringsholm, B., & Steentoft, A. (1993) · International Journal of Legal Medicine · doi:10.1007/bf01225229 · Cited by 32
Agonist activity of N-desmethylclozapine at δ-opioid receptors of human frontal cortex
Olianas, M. C., Dedoni, S., Ambu, R., & Onali, P. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.02.025 · Cited by 31
Huang, X., Tan, Y. Y., Huang, X., & Wang, Q. (2007) · Neuroscience Research · doi:10.1016/j.neures.2007.08.001 · Cited by 28
Kobayashi, T., Ikeda, K., & Kumanishi, T. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701621 · Cited by 28
Bastiampillai, T. J., Forooziya, F., & Dhillon, R. (2009) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670802653398 · Cited by 26
Clozapine as a drug of dependence
Goudie, A. J., Smith, J. A., Robertson, A., & Cavanagh, C. (1999) · Psychopharmacology · doi:10.1007/s002130050901 · Cited by 25 · cited 1×
“In association with a sudden discontinuation of clozapine, which may be required in cases of blood dyscrasia or suspected myocarditis, instances of withdrawal have already been reported [6,44,54,55].”
BackgroundAcute overdosage with clozapine : a review of the available clinical experience
Blaye, I. L., Donatini, B., Hall, M., & Krupp, P. F. (1992) · Pharmaceutical Medicine · Cited by 24
Neuroleptic Blockade of the Effect of Various Neurotransmitter Substances
Fjalland, B., & Boeck, V. (1978) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1978.tb02191.x · Cited by 23 · cited 2×
“Conversely, the clinical effects of the reported interactions at 5HT2C; 5HT1A; 5-HT6; and 5-HT7 receptors [6] might be less clear; (3) α2C-adrenergic receptor blockade; this may contribute to the clozapine-related improvement of cognitive function [7]; (4) significant antimuscarinic and antihistaminergic H1 effects, w…”
BackgroundGeographical disparities in prescription practices of lithium and clozapine: a community‐based study
Verdoux, H., Pambrun, É., Cortaredona, S., Coldefy, M., Neindre, C. L., Tournier, M., & Verger, P. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12554 · Cited by 23
Galova, A., Berney, P., Desmeules, J. A., Sergentanis, I. N., & Besson, M. J. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2055-1 · Cited by 23 · cited 2×
“There are no established guidelines regarding which antipsychotic to choose after withdrawal of clozapine [73], although anticholinergics and olanzapine may be the treatment of choice for preventing withdrawal [53].”
BackgroundResultCatatonia Following Abrupt Stoppage of Clozapine
Kumar, S., Sur, S., & Singh, A. (2011) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2011.564135 · Cited by 21 · cited 1×
“Consistent with this, symptoms appear to regress rapidly with the help of anti-cholinergic drugs; c) a serotonergic syndrome, which may occur even without the concomitant use of a serotonergic agent [10,39,61].”
BackgroundClozapine withdrawal emergent dystonia, oculogyric crisis and rebound psychosis in a single patient
Sarma, S., Chetia, D., Raha, B., & Agarwal, G. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315591928 · Cited by 18
Recurrent clozapine and lorazepam withdrawal psychosis with catatonia
Wang, B. Z., Gupta, A., Bastiampillai, T. J., & Sani, F. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412444992 · Cited by 17 · cited 1×
“This may involve possible severe and long-lasting symptoms [10,59,67,84].”
BackgroundThe art of clozapine therapy and “clozaphobia”
Pandarakalam, J. P. (2019) · BMJ · doi:10.1136/bmj.l484 · Cited by 16 · cited 1×
“In being a prescribed drug of highly significant clinical value [85], increased awareness is essential towards prevention, diagnosis, and treatment of cases of clozapine abuse/recreational use in patients diagnosed with schizophrenia [86].”
BackgroundPiccini, G., Ceroni, P., Marchesi, C., Maggini, C., & Maestri, G. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.170.3.290b · Cited by 13
Hemoperfusion in the Treatment of Acute Clozapine Intoxication in China
He, J., Xiang, Y., Li, W.-B., Cai, Z., & Ungvari, G. S. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815a5881 · Cited by 13 · cited 1×
“altered state of consciousness [4,81,82]; clozapine high-dosage ingestion may be associated with a mortality rate of approximately 12% [83], with fatalities most typically being associated with cardiac insufficiency and aspiration pneumonia observed with dosages higher than 2 g [45–48].”
BackgroundSudden-Onset Catatonia Following Clozapine Withdrawal
Koychev, I. G., Hadjiphilippou, S., Lynch, J., Whelan, P., & MacCabe, J. H. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15cr10355 · Cited by 13 · cited 1×
“In association with a sudden discontinuation of clozapine, which may be required in cases of blood dyscrasia or suspected myocarditis, instances of withdrawal have already been reported [6,44,54,55].”
BackgroundManaging clozapine discontinuation – acute and chronic maintenance strategies
Shields, M. K., Bastiampillai, T. J., & Mohan, T. S. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867411432215 · Cited by 9 · cited 3×
“flexibility, staring, posturing, mannerisms, negativism, and also restless, irrelevant speech, and psychomotor agitation [6,67].”
BackgroundMisuse of Trihexyphenidyl (Artane) on Réunion Island
Torrents, R., Ferre, J. F., Konareff, A., Hemery, P., Sherwin, K., Lassalle, C., Simon, N., & Scerra, S. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000882 · Cited by 9
Schizophrenia and Other Psychoses
Lawrence, R. E., First, M. B., & Lieberman, J. A. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch48 · Cited by 9
Solismaa, A., Kampman, O., Lyytikäinen, L., Seppälä, N., Viikki, M., Mononen, N., Lehtimäki, T. J., & Leinonen, E. V. J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000885 · Cited by 7 · cited 1×
“Hypothetically, putative levels of clozapine misuse liability might be tentatively explained considering the range of its pharmacodynamics activities, and the occurrence of rewarding and pleasurable effects due to the agonism at both delta-opioid [13,17,75] and cannabinoid CB1 receptors [18]; and the antagonism at mus…”
Background[Clozapine withdrawal. A review].
Szafrański, T., & Gmurkowski, K. (1999) · PubMed · Cited by 5
Breen, E. G. (2017) · BJPsych Bulletin · doi:10.1192/pb.41.6.366 · Cited by 3
Trends in the prescription of clozapine in a psychiatric hospital: a 5-year observational study
Niehues, G. D., Balan, A. B., Prá, V. B., Pellizzaro, R. S., da Silva, P. R. A., Niehues, M. D., Costa, A. P., Schwarzbold, M. L., & Díaz, A. P. (2017) · Trends in Psychiatry and Psychotherapy · doi:10.1590/2237-6089-2016-0053 · Cited by 2
Research works printed but not linked: 5
- Stahl S.M. Stahl’s Essential Psychopharmacology-Prescriber’s Guide 6th ed. Cambridge University Press Cambridge, UK 2017
- Aronson J.K. Clozapine Meyler’s Side Effects of Drugs (Sixteenth Edition): The International Encyclopedia of Adverse Drug Reactions and Interactions Elsevier Kidlington, UK 2016 443 477
- European Medicines Agency (EMA) ICH Guideline E2B (R3) on Electronic Transmission of Individual Case Safety Reports (ICSRs)—Data Elements and Message Specification—Implementation Guide Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-4.pdf (accessed on 25 July 2019)
- Bastiampillai T. Forooziya F. Dhillon R. Clozapine-withdrawal catatonia Aust. N. Z. J. Psychiatry 2013 43 283 284 19230235
- Ines S. Mahal A. Hoss J. Gaertner H.J. Intoxication with clozapine: Plasma levels above 9000 ng/mL. Typical clinical picture diagnostic confusion (abstract) Neuropsychopharmacology 1994 10 122S
Cited by
Blackman, G., Oloyede, E., Horowitz, M., Harland, R., Taylor, D., MacCabe, J., & McGuire, P. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab103 · Cited by 48
Chiappini, S., Schifano, F., Corkery, J., & Guirguis, A. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959615 · Cited by 47
Self-citationRafizadeh, R., Danilewitz, M., Bousman, C. A., Mathew, N., White, R. F., Bahji, A., Honer, W. G., & Schütz, C. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221142575 · Cited by 41
“Clozapine safety in individuals with comorbid SUDs A descriptive analysis of the European Medicines Agency Pharmacovigilance Database (Chiappini et al., 2020) explored cases reported due to adverse drug reactions (ADRs) related to clozapine.”
BackgroundThe e-psychonaut drugs’ psychopharmacology
Schifano, F., Chiappini, S., Corkery, J., Scherbaum, N., & Guirguis, A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.02.008 · Cited by 34
“Finally, although difficult to be interpreted, misuse/abuse cases of clozapine ingestion as an NPS have been described [43].”
BackgroundSelf-citationFountoulakis, K. Ν., Moeller, H.-J., Kasper, S. F., Tamminga, C. A., Yamawaki, S., Kahn, R. S., Tandon, R., Correll, C. U., & Javed, A. (2020) · CNS Spectrums · doi:10.1017/s1092852920001546 · Cited by 34
“A special case of withdrawal is clozapine withdrawal syndrome, which is solidly proven concerning a variety of adverse events.(103) It has been reported that when discontinuation is abrupt, it could involve rebound psychosis,(104) delirium,(105) serotonin syndrome,(106) catatonia,(107-109) extrapyramidal adverse event…”
Background
Metadata
- Authors
- Chiappini, S., Schifano, F., Corkery, J. M., & Guirguis, A.
- Affiliations
- University of Hertfordshire (GB)
- Swansea University (GB)
- Corresponding author
- Schifano, Fabrizio
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2020-02-16
- Volume
- 10
- Issue
- 2
- Pages
- 105
- ISSN
- 2076-3425 (ISSN-L)
- PMC
- PMC7071448
- OpenAlex
- W3005893007
- Cited by
- 33
- References
- 78
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 9 · 2020: 6
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Brain Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion, cc-by)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Keywords
- clozapine, drug addiction, adverse drug reactions, pharmacovigilance, intentional drug overdose, suicide, substance abuse, polydrug abuse, treatment-resistant schizophrenia, recreational drug use
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.